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Abstract: The silver nanoparticle (AgNP) is a candidate for anticancer therapy because of its 
effects on cell survival and signaling. Although numerous reports are available regarding their 
effect on cell death, the effect of AgNPs on metabolism is not well understood. In this study, 
we investigated the effect of AgNPs on glucose metabolism in hepatoma cell lines. Lactate 
release from both HepG2 and Huh7 cells was reduced with 5 nm AgNPs as early as 1 hour 
after treatment, when cell death did not occur. Treatment with 5 nm AgNPs decreased glucose 
consumption in HepG2 cells but not in Huh7 cells. Treatment with 5 nm AgNPs reduced nuclear 
factor erythroid 2-like 2 expression in both cell types without affecting its activation at the 
early time points after AgNPs’ treatment. Increased reactive oxygen species (ROS) production 
was detected 1 hour after 5 nm AgNPs’ treatment, and lactate release was restored in the pres-
ence of an ROS scavenger. Our results suggest that 5 nm AgNPs affect glucose metabolism 
by producing ROS.
Keywords: metal nanoparticles, carbohydrate metabolism, lactic acid, cytotoxicity
Introduction
Silver nanoparticles (AgNPs) have been studied for their effectiveness in the treatment 
of cancer and infection. AgNPs have been shown to induce death of acute myeloid 
leukemia and breast cancer cells.1,2 Additionally, AgNPs conjugated with folic acid are 
preferentially taken up by human ovary cancer cells, inducing an efficient therapeutic 
response to irradiation with a continuous wave near-infrared laser.3 In addition to 
anticancer activity, inhibitory effects of AgNPs against various pathogens, including 
bacteria such as Escherichia coli, fungi such as Candida species, and viruses such as 
herpes simplex viruses, have been reported.4–6
AgNP-mediated cytotoxicity has been linked with various cellular processes. AgNPs 
enter the cytosol, mitochondria, and nucleus,7 and uptake of AgNPs has been implicated 
in their cytotoxicity. AgNPs have been observed in the cytosol of monocytes, which 
are susceptible to AgNP-mediated cytotoxicity, but not in T-cells, which are resistant 
to AgNP-mediated cytotoxicity.8 Once inside susceptible cells, AgNPs can damage the 
mitochondria, reduce ATP content, increase reactive oxygen species (ROS) production, 
damage DNA, and ultimately lead to cell death.7 AgNPs can activate p53, extracellular 
signal-regulated kinase (Erk)1/2, and caspase signaling and downregulate B-cell CLL/
lymphoma 2 (Bcl2), resulting in apoptosis.9 AgNPs exhibit a strong affinity for the 
thiol groups found in the antioxidant glutathione (GSH) and may deplete GSH levels 
in cells; depletion of GSH has been shown to increase the cytotoxicity of AgNPs.10–12 
A recent report showed an association between autophagy and AgNP cytotoxicity by 
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demonstrating that cell death in AgNP-treated cells increased 
when autophagy was inhibited.13 In addition, a preferential 
cytotoxic effect of AgNPs was observed in cells of a breast 
cancer subtype compared to non-tumorigenic cells derived 
from the breast, liver, kidney, and monocyte lineages, although 
the underlying mechanisms were not been determined.12
Metabolic reprogramming of tumor cells has emerged 
as a new therapeutic strategy.14 The first metabolic change 
discovered in tumor cells was the switch from oxidative 
phosphorylation of glucose to aerobic glycolysis.15 Aerobic 
glycolysis is characterized by increased glucose uptake and 
lactate release in the presence of oxygen.15 Inactivation of 
lactate dehydrogenase A, which is involved in the last step 
of aerobic glycolysis, has been shown to suppress tumor 
growth in a mouse model.16 Rapidly growing tumor cells 
require exogenous glycine and concomitant activation of 
the glycine synthesis pathway in mitochondria to promote 
growth.17 Tumor cells exhibit different sensitivities to vari-
ous molecules that inhibit glycolysis, glutamine metabolism, 
lipid synthesis, and regulation of redox balance. The sensitiv-
ity of a tumor is dependent on its metabolic type, which is 
determined by the preferred pathway of glucose, glycolysis, 
or lipogenesis.18 It was recently shown that the cytotoxicity of 
melatonin in tumor cells is associated with its suppression of 
aerobic glycolysis.19 However, the effect of AgNPs on tumor 
cell metabolism has not yet been completely determined.
A recent report demonstrated that zinc oxide nanopar-
ticles, but not titanium dioxide nanoparticles, enhanced 
glycogenolysis, gluconeogenesis, and glycolysis in a hepa-
toma cell line.20 In this study, we examined the effect of 
AgNP treatment on glucose metabolism, such as glucose 
consumption and lactate release, in human hepatoma cell 
lines. We found that 5 nm AgNPs but not 100 nm AgNPs 
affected glucose consumption and lactate release as well as 
the transcription of molecules regulating glucose metabolic 
pathways. Additionally, we demonstrated that the 5 nm 
AgNP-mediated reduction in lactate release was restored by 
treating hepatoma cells with an ROS scavenger.
Materials and methods
chemicals
AgNPs of mean sizes 5 and 100 nm were coated with poly-
vinylpyrrolidone (I&C Technology, Seoul, Korea).
Characterization of AgNPs was previously described.21 
Briefly, the average size of AgNPs determined using transmis-
sion electron microscopy (model JEM-1011, JEOL, Tokyo, 
Japan) was 7.9±5.3 nm for 5 nm AgNPs and 70.9±71.3 nm 
for 100 nm AgNPs. AgNPs of 5 nm were round and relatively 
uniform, whereas 100 nm AgNPs showed a range of different 
sized particles with most being larger than 50 nm. Agglom-
eration states of AgNPs in serum-free Roswell Park Memorial 
Institute (RPMI) 1640 medium (Thermo Fisher Scientific, 
Waltham, MA, USA) at 1, 10, and 100 mg/mL were analyzed 
using dynamic light scattering analysis (Novato, CA, USA). 
Dynamic light scattering showed that the mean diameter of 
AgNPs was 3.7 and 95.9 nm for 5 nm and 100 nm AgNPs, 
respectively. N-Acetylcysteine (NAC) was purchased from 
Sigma-Aldrich (St Louis, MO, USA). Propidium iodide was 
purchased from Millipore (Billerica, MA, USA).
cell lines and culture
The HepG2 cell line (American Type Culture Collection 
[ATCC], Manassas, VA, USA) was originally derived from 
a hepatocellular carcinoma in a 15-year-old Caucasian boy, 
and the THP-1 cell line (ATCC) from an acute monocytic 
leukemia in a 1-year-old male child. The Huh7 cell line 
(Japanese Collection of Research Bioresources Cell Bank) 
was originally derived from a hepatocellular carcinoma in 
a 57-year-old Japanese man. The HepG2 and Huh7 cells 
were cultured in Dulbecco’s Modified Eagle’s Medium 
(Thermo Fisher Scientific) containing 10% fetal bovine 
serum (Thermo Fisher Scientific), penicillin (100 U/mL, 
Thermo Fisher Scientific), and streptomycin (100 µg/mL, 
Thermo Fisher Scientific). The THP-1 cells were cultured 
in Roswell Park Memorial Institute 1640 (Thermo Fisher 
Scientific) medium containing 10% fetal bovine serum 
and penicillin–streptomycin (100 U/mL and 100 µg/mL, 
respectively) at 37°C in a humidified 5% CO
2
 incubator. Cells 
that were passaged between 5 and 40 times after thawing 
were used in the experiments. Ajou University’s Institutional 
Review Board determined this study to be exempt (AJIRB-
BMR-EXP-15-426).
assessment of glucose consumption and 
lactate production
AgNPs were added to the culture of hepatoma cell lines 
(HepG2 or Huh7 cells) or THP-1 cells. Glucose consumption 
and lactate production were analyzed using a YSI biochemi-
cal analyzer (YSI Life Sciences, Simpsonville, SC, USA). In 
experiments to block the effect of ROS, 1 mM NAC was added 
to the culture media 30 minutes before AgNP treatment.
assessment of cell viability
Cell viability was assessed by labeling with propidium iodide 
and flow cytometry using a fluorescent-activated cell sorter 
canto (BD Biosciences, Franklin Lakes, NJ, USA) apparatus.
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
57
agNPs affect glucose metabolism in hepatoma cells via rOs production
Western blot analysis
Cells were lysed using RIPA buffer for 6-phosphofructo- 
2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) detection. 
To analyze nuclear factor erythroid 2-like 2 (Nrf2) levels, 
cytosolic and nuclear compartments were extracted first 
with cytosol extraction buffer containing HEPES (10 mM) 
pH 7.9, KCl (10 mM), EDTA (0.1 mM), 0.3% NP-40, and 
protease inhibitors and then with nucleus extraction buffer 
containing HEPES (20 mM) pH 7.9, NaCl (0.4 mM), EDTA 
(1 mM), 0.25% glycerol, and protease inhibitors. The cell 
lysate was subjected to Western blot analysis using anti-
PFKFB3 antibody (Ab) (Abgent, San Diego, CA, USA), 
anti-Nrf2 Ab (Santa Cruz Biotechnology, Dallas, TX, USA), 
anti-actin Ab (Bethyl Laboratories Inc., Montgomery, TX, 
USA), or anti-lamin A/C Ab (Santa Cruz) as a primary Ab 
and horseradish peroxidase-conjugated anti-rabbit IgG Ab 
(Thermo Fisher Scientific) as a secondary Ab. Signals were 
detected using enhanced chemical luminescence (Amersham, 
Piscataway, NJ, USA). The immunoblot was digitized using 
an office scanner (UMAX Astra 4100, Taipei, Taiwan), and 
the intensity of the band of the expected molecular size was 
quantitated using Image Gauge V 4.0 (Fujifilm Corporation, 
Tokyo, Japan). The band intensity of PFKFB3 and cytosolic 
Nrf2 was normalized to actin, and nuclear Nrf2 was normal-
ized to lamin.
rNa isolation and quantitative reverse 
transcription-polymerase chain reaction
RNA was isolated from cells treated with AgNPs for the 
indicated time using RNA STAT-60 (Tel-Test, Friendswood, 
TX, USA). RNA was subjected to quantitative reverse 
transcription-polymerase chain reaction using primer sets 
specific to hexokinase-2, PFKFB-3, phosphoenolpyruvate 
carboxylase (PEPCK)-C, PEPCK-M, Nrf2, transketolase 
(TKT), phosphogluconate dehydrogenase (6PGD), glucose-
6-phosphate dehydrogenase (G6PDH), and transaldolase 
(TALDO1) (Bioneer, Daejeon, Korea) and Sybr Premix Ex 
Taq (TaKaRa-Bio, Shiga, Japan). The expression level of 
each gene was normalized to the expression of actin.
assessment of intracellular rOs
Cells were treated with AgNPs for 30 minutes and 1, 2, and 
3 hours and then harvested. Cells were washed and then 
treated with 2,7-dichlorofluorescin diacetate (Thermo Fisher 
Scientific) in Hank’s Balance Salt Solution for 30 minutes 
at 37°C. Fluorescence intensity was analyzed using a 
fluorescent-activated cell sorter canto apparatus.
statistics
Student’s t-test was performed, and P-values were deter-
mined to identify significant differences, as indicated in the 
figures.
Results
Decreased lactate release in cells treated 
with 5 nm agNPs
We assessed the effect of AgNP treatment on glucose 
consumption and lactate production. Because the size of 
AgNPs is a critical determinant of therapeutic activity and 
toxicity, we compared the effects of 5 nm AgNPs with 
those of 100 nm AgNPs in HepG2 and Huh7 cells. Glucose 
consumption over 3 hours was significantly decreased in 
HepG2 cells treated with 0.5–7.5 µg/mL 5 nm AgNPs in a 
concentration-dependent manner (P,0.005) but not in cells 
treated with 100 nm AgNPs (Figure 1A). Glucose consump-
tion was not significantly altered in Huh7 cells (Figure 1D) 
or THP-1 cells with or without lipopolysaccharide (LPS) 
(Figure 1G) treated with 5 and 100 nm AgNPs, whereas 
treatment of HepG2 cells with AgNPs for 6 hours did affect 
glucose consumption (Figure S1). Notably, treatment with 
5 nm AgNPs, but not 100 nm AgNPs, significantly reduced 
lactate production in HepG2, Huh7, and LPS-stimulated 
THP-1 cells in a concentration-dependent manner (P,0.005) 
(Figure 1B, E, and H). Cell viability of HepG2 cells treated 
with 5 µg/mL and 7.5 µg/mL 5 nm AgNPs was reduced to 
90.2% and 61.1%, respectively, but the extent of the reduc-
tion in lactate release was similar at both concentrations of 
AgNP (Figure 1C). In addition, when HepG2 cell viability 
was 92.2% after 6 hours of treatment with 0.5 µg/mL 5 nm 
AgNPs, lactate release was not reduced (Figure S1). For 
Huh7 cells, cell viability was not significantly reduced by 
treatment with AgNPs for 3 hours (Figure 1F). The viability 
of LPS-stimulated THP-1 cells was reduced to 61.4% after 
treatment with 5 µg/mL 5 nm AgNPs and to approximately 
20.8% after treatment with 7.5 µg/mL 5 nm AgNPs, but 
the extent of reduction in lactate release was similar at both 
concentrations of AgNPs (Figure 1I). Taken together, these 
results demonstrated that 5 nm AgNPs reduced lactate release 
in cells in a dose-dependent manner.
We next examined the kinetic effect of 5 µg/mL AgNPs 
(Figure 2). Glucose consumption was significantly decreased 
in HepG2 cells 2 hours after treatment with 5 nm AgNPs 
compared to untreated cells and cells treated with 100 nm 
AgNPs (Figure 2A). The decrease in lactate production 
was detected at 1 hour after 5 nm AgNP treatment, in both 
HepG2 and Huh7 cells (Figure 2B and E). Cell viability 
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was reduced by 7.2% in HepG2 cells only 3 hours after 
treatment with 5 nm AgNPs. These results indicate that the 
decrease in lactate release caused by 5 nm AgNP treatment 
may occur earlier than the decrease in glucose consumption 
and cell viability.
Decreased mrNa levels of Nrf2 in cells 
treated with 5 nm agNPs
Glucose is metabolized into lactate through glycolysis 
or generated through gluconeogenesis using substrates 
such as lactate, amino acids, or glycerol in hepatocytes.22 
Additionally, glucose is utilized in the pentose phosphate 
pathway (PPP), in which nicotinamide adenine dinucleotide 
phosphate hydrogen is synthesized.23 Thus, lactate produc-
tion is reduced if the flux of glucose to glycolysis decreases 
and/or preferentially diverts to PPP or if gluconeogenesis 
is increased. To determine whether glucose metabolism is 
altered by treatment with 5 nm AgNPs, we examined the 
expression and activation of molecules regulating glyco-
lysis, PPP, or gluconeogenesis. Hexokinase 2 is involved 
Figure 2 lactate release by hepatoma cell lines was reduced following treatment with 5 nm agNPs for 1 hour or more.
Notes: hepg2 (3×105/ml, A, C, and E) and huh7 cells (2×105/ml, B, D, and F) were treated with 5 µg/ml 5 or 100 nm agNPs for the indicated times. glucose consumption 
(A and B) and lactate release (C and D) in culture media were measured using a YsI biochemical analyzer. cell viability (E and F) was analyzed by labeling with propidium 
iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in hextuplicate. *P,0.005.
Abbreviation: agNPs, silver nanoparticles.
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in the conversion of glucose to glucose-6-phosphate, a 
step shared by glycolysis and PPP. Hexokinase 2 messen-
ger RNA (mRNA) levels in both HepG2 and Huh7 cells 
treated with AgNPs for 3 hours were not significantly dif-
ferent from those in negative controls (Figure 3). PFKFB3 
catalyzes the conversion of fructose-6-phosphate to 
fructose-2,6-bisphosphate, which promotes glycolysis and 
suppresses gluconeogenesis, whereas PFKFB3 directs PPP 
when its arginine residues (R131/R134) are not methylated 
or its cysteine residue is glutathionylated.22,24,25 Although 
the mRNA levels of PFKFB3 were not significantly altered 
by treatment with 5 nm AgNPs for 3 hours, its protein 
Figure 3 Transcript levels of hK2, PFKFB3, PePcK-c, and PePcK-M in hepatoma cells treated with agNPs.
Notes: hepg2 (3×105/ml, A, C, E, and G) and huh7 cells (2×105/ml, B, D, F, and H) were treated with the indicated concentrations of 5 or 100 nm agNPs for 
3 hours. Transcript levels were analyzed by real-time rT-Pcr. Data are shown as the mean ± standard deviation of three or more independent experiments.
Abbreviations: agNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; PePcK-c, phosphoenolpyruvate carboxylase; rT-Pcr, 
reverse transcription polymerase chain reaction; mrNa, messenger rNa.
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levels were generally increased in HepG2 cells treated 
with 7.5 µg/mL 5 nm AgNPs (Figures 3 and 4). At early 
time points after treatment of hepatoma cells with 5 nm 
AgNPs, the mRNA levels of PFKFB3 were not significantly 
changed (Figure 5A and B). Cytoplasmic and mitochondrial 
PEPCK-C and PEPCK-M are involved in gluconeogen-
esis, using lactate as a substrate.22,26 Both PEPCK-C and 
PEPCK-M mRNA levels were not significantly altered in 
hepatoma cell lines treated with AgNPs for 3 hours compared 
to those in negative controls (Figure 3). Nrf2 participates in 
glucose metabolism by regulating the expression of enzymes 
involved in the PPP, such as G6PDH, 6PGD, TKT, and 
TALDO.27 We analyzed the effect of AgNPs on Nrf2 mRNA 
levels and found that 5 nm AgNPs significantly reduced 
Nrf2 mRNA levels in both HepG2 and Huh7 cells 2 and 
3 hours after treatment with AgNPs, respectively (Figure 5). 
These results suggest that treatment with 5 nm AgNP affects 
glucose metabolism, since AgNPs altered the expression of 
Nrf2, a regulator of PPP.
Increased production of rOs without 
concurrent Nrf2 activation in cells 
treated with 5 nm agNPs
Increased ROS production was previously reported in cells 
treated with AgNPs, and elevated ROS levels were found to 
be associated with Nrf2 activation to protect cells via nicoti-
namide adenine dinucleotide phosphate hydrogen-mediated 
removal of ROS.1,28–31 Thus, we tested whether 5 nm AgNPs 
led to ROS production in hepatoma cells and activated Nrf2. 
Significantly more ROS were produced in HepG2 and Huh7 
cells starting at 1 hour and 30 minutes after treatment with 
5 nm AgNPs, respectively, compared with negative controls 
and cells treated with 100 nm AgNPs (Figure 6). Further, 
5 nm AgNP-induced ROS levels were downregulated in the 
presence of an ROS scavenger. We then examined the trans-
location of Nrf2 to the nucleus after treatment with AgNPs. 
Nrf2, which is preferentially located in the cytoplasm, moved 
to the nucleus under elevated ROS levels and induced the 
transcription of genes harboring antioxidant response elements, 
including G6PDH, 6PGD, TKT, and TALDO, which are 
involved in the PPP.31 After treatment of HepG2 and Huh7 
cells with AgNPs for 1 hour, increased ROS production and 
decreased lactate release were detected. We then analyzed 
Nrf2 levels at the indicated times in the cytosolic and nuclear 
fractions of the cell lysate using Western blotting (Figure 7). 
Because of the low Nrf2 levels in the nuclear fraction, the load-
ing amount of the nuclear fraction was threefold higher than that 
of the cytosolic fraction. Nuclear Nrf2 density was normalized 
as follows, owing to contamination of nuclear compartment 
with cytosolic fraction: [nuclear Nrf2 intensity - cytosolic Nrf2 
intensity × nuclear actin intensity/(cytosolic actin intensity ×3)]/
nuclear lamin density. Unexpectedly, Nrf2 protein levels in the 
nucleus were not significantly increased in hepatoma cells 
treated with 5 nm AgNPs compared with negative controls 
Figure 4 Protein levels of PFKFB3 in hepatoma cells treated with agNPs.
Notes: hepg2 (3×105/ml, A) and huh7 cells (2×105/ml, B) were treated with the indicated concentrations of 5 or 100 nm agNPs for 3 hours. PFKFB3 expression was 
analyzed by Western blotting. a representative blot is shown and the normalized band intensity is displayed. Data are shown as the mean ± standard deviation of five 
independent experiments.
Abbreviations: agNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3.
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Figure 5 Transcript levels of PFKFB3 and Nrf2 in hepatoma cells treated with agNPs for various times.
Notes: hepg2 (3×105/ml, A and C) and huh7 cells (2×105/ml, B and D) were treated with 5 µg/ml 5 or 100 nm agNPs for the indicated times. relative transcript levels 
were normalized to actin mrNa level and analyzed by real-time rT-Pcr. Data are shown as the mean ± standard deviation of three independent experiments conducted in 
triplicate. *P,0.005 vs negative control, **P,0.005 vs 100 nm.
Abbreviations: agNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; Nrf2, nuclear factor erythroid 2-like 2; mrNa, messenger 
rNa; rel, relative level of; rT-Pcr, reverse transcription polymerase chain reaction.
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(P.0.01). Additionally, there was no difference in the mRNA 
levels of genes induced by Nrf2, such as G6PDH, 6PGD, TKT, 
and TALDO, between cells treated with AgNPs and negative 
controls (Figure S2). Taken together, these results demonstrate 
that treatment of hepatoma cells with 5 nm AgNPs increased 
ROS production without activating Nrf2.
rOs scavenger-mediated restoration of 
lactate release in cells treated with 5 nm 
agNPs
Finally, we investigated whether ROS production was 
responsible for the reduced release of lactate by hepatoma 
cells treated with 5 nm AgNPs. We added the ROS scav-
enger NAC to the hepatoma cell culture prior to treatment 
with AgNPs and then analyzed glucose consumption, lactate 
release, and cell viability (Figure 8). Reduced glucose con-
sumption by HepG2 cells and lactate release by both hepa-
toma cell lines following treatment with 5 nm AgNPs were 
restored after the addition of NAC. These results showed that 
ROS production induced by 5 nm AgNPs reduced lactate 
release by the hepatoma cell lines.
Discussion
We showed that 5 nm AgNPs altered glucose metabolism 
in two different hepatoma cell lines and in THP-1 cells. 
Reductions in lactate release and Nrf2 transcript levels were 
observed in both HepG2 and Huh7 cells treated with 5 nm 
AgNPs. Further, we found that increased ROS production 
by 5 nm AgNP treatment reduced lactate release.
Our results showed an early effect of AgNPs on glucose 
metabolism in cells. The reduced release of lactate by hepa-
toma cell lines was observed from 1 to 6 hours after treatment 
with 5 nm AgNPs (Figures 1, 2, and S1). A recent report by 
Chen et al demonstrated a late effect of AgNPs on energy 
metabolism in several cell lines, including HepG2 cells.32 
In that report, the metabolic shift from oxidative phospho-
rylation to glycolysis (ie, increased lactate production) was 
observed 24 hours after treatment with AgNPs. In addition 
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Figure 6 reactive oxygen species (rOs) production in hepatoma cells treated with agNPs.
Notes: hepg2 (3×105/ml, A and B) and huh7 cells (2×105/ml, C) were treated with 5 µg/ml 5 or 100 nm agNPs; 5 nm agNPs following pretreatment with Nac (1 mM) 
or h2O2 for the indicated times. ROS production was determined by DCFDA labeling and flow cytometric analysis. A representative histogram (A) of hepg2 at 3 hours and 
relative percentage of mean fluorescence intensity of two independent experiments conducted in duplicate are shown (B and C). Data are shown as the mean ± standard 
deviation.
Abbreviations: AgNPs, silver nanoparticles; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; DCFDA, 2,7-dichlorofluorescin diacetate; NAC, N-acetylcysteine; 
MFI, mean fluorescence intensity.
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to this difference in time of analysis after AgNP treatment, 
there were several other differences between our study and 
Chen et al, including: 1) the size of AgNPs; we used 5 nm 
particles, while they used 20 nm or larger particles; 2) we 
analyzed lactate release into the media, while they measured 
intracellular lactate; 3) we observed increased ROS produc-
tion, but they did not; 4) we observed a dose-dependent 
decrease in cell viability for 6 hours after treatment with 
AgNPs, but they did not, for 24 hours, using the same concen-
trations of AgNPs; 5) mRNA levels of PFKFB3 in our study 
did not significantly increase and its protein levels increased 
only at a high concentration of AgNP treatment at 3 hours 
in HepG2 cells, whereas they found an increase in PFKFB3 
mRNA levels at 24 hours and no data regarding protein lev-
els were included. Miethling-Graff et al observed size- and 
dose-dependent effects of AgNPs on ROS production: 1) 5 or 
10 µg/mL 10 nm AgNPs increased ROS levels by more than 
1.9- or 2.6-fold, respectively, compared to 20, 40, and 60 nm 
AgNPs; 2) the cytotoxicity of AgNPs showed an inverse 
relationship with particle size.30 Similar to Miethling-Graff’s 
report, we detected elevated ROS levels after 5 nm AgNP 
treatment, whereas Chen et al did not detect ROS produc-
tion after 20 nm AgNP treatment. We observed that elevated 
ROS production played a major role in the reduced release 
of lactate following 5 nm AgNP treatment, suggesting that 
metabolic changes caused by AgNPs may depend on the their 
size. Regarding PFKFB3, the protein levels of PFKFB3 were 
measured by Western blot and not based only on mRNA 
levels, suggesting alterations in protein degradation.33 Since 
PFKFB3 can direct the glucose metabolic pathway to glyco-
lysis or to PPP, based on its methylation status,25 additional 
studies are needed to clarify the effect of PFKFB3 on glucose 
metabolism with AgNP treatment.
Glucose consumption was significantly reduced in 
HepG2 cells but not in Huh7 and THP-1 cells. Although 
5 nm AgNPs reduced lactate release in both HepG2 and 
Huh7 cells and in THP-1 cells stimulated with LPS, 5 nm 
AgNPs did not affect lactate release by THP-1 cells in the 
absence of LPS stimulation. The reasons for these differential 
responses to AgNP treatment are not well-understood, but 
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Figure 7 activation of Nrf2 in hepatoma cells treated with agNPs.
Notes: hepg2 (3×105/ml, A) and huh7 cells (2×105/ml, B) were treated with 5 µg/ml 5 or 100 nm agNPs for the indicated times. cytosolic and nuclear Nrf2 were 
analyzed by Western blotting. a representative blot is shown and the normalized band intensity is displayed. Data are shown as the mean ± standard deviation of four to six 
independent experiments. *P,0.01 vs 0 time.
Abbreviations: agNPs, silver nanoparticles; Nrf2, nuclear factor erythroid 2-like 2; rel, relative level of.
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several factors may be involved, including the relative con-
tribution of metabolic pathways for energy metabolism or 
differences in the expression levels and activation status of 
metabolism regulatory molecules. In agreement with this, 
various respiration rates were observed in cells depending 
on the cell type.34 Overall, gene expression profiles were 
similar, but there were differences in the expression of sev-
eral genes between HepG2 and Huh7 cells.35 Our findings 
suggest that the effect of AgNPs on metabolism may vary 
according to cell type, and thus further study is necessary 
to determine the effect of AgNPs on metabolism in the dif-
ferent types of cells.
In our study, PEPCK mRNA levels were not altered, 
but Nrf2 level was reduced in hepatoma cells 2 hours after 
AgNP treatment. Further, Nrf2 protein levels and nuclear 
localization were not significantly increased in hepatoma 
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Figure 8 restoration of lactate release in hepatoma cells treated with agNPs in the presence of an rOs scavenger.
Notes: hepg2 (3×105/ml, A, C, and E) and huh7 cells (2×105/ml, B, D, and F) were pretreated with 1 mM Nac and then treated with 5 µg/ml 5 nm agNPs for 3 
hours. glucose consumption (A and B) and lactate release (C and D) in the culture media were measured using a YsI biochemical analyzer. cell viability (E and F) was 
analyzed by labeling with propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in triplicate 
or hextuplicate. *P,0.005.
Abbreviations: agNPs, silver nanoparticles; rOs, reactive oxygen species; Nac, N-acetylcysteine.
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cells within 1 hour after treatment with AgNPs. In contrast 
to our results, AgNPs (15 µg/mL) elevated Nrf2 mRNA 
(approximately 1.8-fold) and protein levels in Caco-2 cells, 
a human colorectal adenocarcinoma cell line, 3 and 6 hours, 
respectively.36 The previous study found elevated Nrf2 
protein levels in the nuclear fraction after normalization 
of nuclear Nrf2 with GAPDH protein levels.36 In another 
report of rainbow trout (Oncorhynchus mykiss) hepatocytes, 
10 µg/mL AgNPs with an average size of 9 nm stimulated 
glycogenolysis and reduced PEPCK activity 48 hours after 
treatment.37 It was not clear whether the alterations in Nrf2 
and PEPCK expression were direct effects or were secondary 
results due to compensation for metabolic changes caused 
by AgNPs.
Conclusion
We demonstrated ROS-dependent reduction of lactate 
release by hepatoma cell lines in response to 5 nm AgNPs. 
Our findings provide important insights into the cytotoxic 
mechanisms of AgNPs.
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Supplementary materials
Figure S1 effect of agNPs on glucose consumption, lactate release, and cell viability in hepatoma cells treated for 6 hours.
Notes: hepg2 (3×105/ml, A, C, and E) and huh7 cells (2×105/ml, B, D, and F) were treated with the indicated concentrations of 5 or 100 nm agNPs for 6 hours. glucose 
consumption (A and B) and lactate release (C and D) in culture media were measured using an YsI biochemical analyzer. cell viability (E and F) was analyzed by labeling with 
propidium iodide and flow cytometry. The data represent the mean ± standard deviation of two independent experiments conducted in triplicate. *P,0.005.
Abbreviation: agNPs, silver nanoparticles.
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Figure S2 Transcript levels of 6PgD, g6PDh, and TalDO1 in hepatoma cells treated with agNPs.
Notes: hepg2 (3×105/ml, A) and huh7 cells (2×105/ml, B) were treated with 5 µg/ml 5 or 100 nm agNPs for 1 hour. Transcript levels were analyzed by real-time rT-Pcr. 
Data are shown as the mean ± standard deviation of two independent experiments conducted in triplicate.
Abbreviations: agNPs, silver nanoparticles; TKT, transketolase; 6PgD, phosphogluconate dehydrogenase; g6PDh, glucose-6-phosphate dehydrogenase; TalDO1, transaldolase; 
mrNa, messenger rNa; rel, relative level of; rT-Pcr, reverse transcription polymerase chain reaction.
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